
(AGENPARL) – SILVER SPRING lun 17 aprile 2023 FDA approves Omisirge (omidubicel-onlv), a nicotinamide modified allogeneic (donor) cord blood-based cell therapy to quicken the recovery time of neutrophils (a subset of white blood cells) in the body and reduce the risk of infection following stem cell transplantation.
Fonte/Source: http://www.fda.gov/news-events/press-announcements/fda-approves-cell-therapy-patients-blood-cancers-reduce-risk-infection-following-stem-cell